Evidence map›Paper›PMID 37716981›Full record

ArticleEuropean journal of medical research2023

Luteolin inhibits A549 cells proliferation and migration by down-regulating androgen receptors.

Xu Li, Yeling Tang, Pengchen Liang, Miaomiao Sun, Tian Li, Zhiping Shen, Shuang Sha

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Xu LiTongji University School of Medicine, Shanghai, 200092, China.
Yeling TangGraduate School, Shanghai University of Traditional Chinese Medicine, Shanghai, 200120, China.
Pengchen LiangSchool of Microelectronics, Shanghai University, Shanghai, 201800, China.
Miaomiao SunGraduate School, Shanghai University of Traditional Chinese Medicine, Shanghai, 200120, China.
Tian LiGraduate School, China Pharmaceutical University, Nanjing, 211198, China.
Zhiping ShenGeneral practice, Tongji University School of Medicine Affiliated Anting Community Health Center of Jiading District, Shanghai, 201805, China. pyszp2010@163.com.
Shuang ShaShanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China. 137511545@qq.com.
Jiading District Central Hospital · CNShanghai University of Traditional Chinese Medicine · CNChina Pharmaceutical University · CNShanghai University · CNShanghai University of Medicine and Health Sciences · CN

Funding

the Construction project of the Shanghai Key Laboratory of Molecular Imaging 18DZ2260400the Health System of Jiading District, Shanghai 2019JDJYXX010the Key Program of National Natural Science Foundation of China 81830052the National Natural Science Foundation of China 81773157the Natural Science Research Project of Jiading District, Shanghai JDKW-2021-0035
6 · The paper itself

Abstract

backgroundYi Fei Qing Hua Granules (YQG) is a traditional Chinese herbal medicine with the effects of inhibiting the proliferation of lung cancer cells. Luteolin is one of the active compounds of YQG. Luteolin is a common flavonoid extracted from natural herbs and it can promote cancer cells apoptosis has been reported. However, the underlying molecular mechanism and effects of luteolin on human lung cancer needs to be validated.

methodsMolecular docking, network pharmacology methods and quantitative structure-activity relationship (QSAR) model were used to identify the active components of YQG and their possible mechanisms of action. Western blot analysis was used to measure AR expression in A549 cells. Cell migration assays were used to detect A549 cells proliferation transfected by AR plasmid and AR mutation plasmid, respectively.

resultsTCMSP search results revealed that there are 182 active compounds in YQG, which correspond to 232 target genes. Sixty-one genes were overlapping genes in the 2 datasets of TCMSP and GeneCards. Through bioinformatics tagging of these overlapping genes, a total of 1,951 GO functional tagging analysis and 133 KEGG pathways were obtained. Through molecular docking technology and QSAR model verification, the multi-target active compound luteolin was screened out as one of the active components of YQG for in vitro verification. Androgen receptor (AR) was the hub protein with the highest docking score of luteolin. Western blot showed that luteolin could inhibit AR protein expression in lung cancer cell line A549. After the phosphorylation site of AR protein 877 was inactivated, the ability of luteolin to inhibit the proliferation of lung cancer cells was weakened. Luteolin significantly inhibited the growth of A549 xenogeneic tumors at day 25 and 28 and inhibited the expression of AR.

conclusionIn this study, we have explored luteolin as one of the active components of YQG, and may inhibit the proliferation and migration of A549 cells by decreasing the expression of AR and the regulation of phosphorylation at AR-binding sites.

Indexed as

Lung NeoplasmsReceptors, AndrogenA549 CellsCell ProliferationHumansLuteolinMolecular Docking SimulationLuteolinReceptors, AndrogenA549 cancer cellsAndrogen receptorLuteolinYi Fei Qing Hua Granules

Identifiers

PMID37716981
PMCPMC10504720
OpenAlexW4386805015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.